Organisation paid for research Program year 2025 Source: CMS Open Payments

North Texas Endocrine Center

Neither a doctor nor a teaching hospital

Research payments

$1,166,159

1,665 payments

Through program year 2025, North Texas Endocrine Center is reported as receiving $1,166,159 in research payments, across 1,665 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$57,421	25
2024	Research	$47,859	7
2023	Research	$111,715	12
2022	Research	$246,768	288
2021	Research	$350,551	1,265
2020	Research	$280,454	46
2019	Research	$71,392	22

Breakdown

Who paid Research payments · program years 2019–2025

Novo Nordisk AS $408,005 1,504 payments
Novartis Pharmaceuticals Corporation $255,485 20 payments
Allergan Inc. $223,311 21 payments
Kowa Research Institute, Inc. $91,374 35 payments
Eli Lilly and Company $88,085 25 payments
AbbVie, Inc. $39,563 32 payments
Lexicon Pharmaceuticals, Inc. $31,446 1 payment
Gilead Sciences, Inc. $17,376 11 payments
Boehringer Ingelheim Pharma GmbH & Co.KG $10,015 3 payments
Boehringer Ingelheim International GmbH $852 11 payments

Studies the money was for Research payments · program years 2019–2025

Nn1436-4625 $328,303 894 payments
A multicenter, randomized, double-blind, dose-conversion study to evaluate the safety and efficacy of HRT w Armour Thyroid compared to levothyroxine (T4) in previously hypothyroid participants, who are on euthyroid T4 replacement $189,609 14 payments
Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (Victorion-2 Prevent) $158,951 9 payments
A Randomized Double-Blind, Placebo-Controlled, Multicenter Trial Assessing the Impact of Lipoprotein (A) Lowering With Tqj230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease $94,534 10 payments
Nn1436-4480 $79,702 610 payments
K-877-302 $61,332 21 payments
Efc-14875 $31,446 1 payment
K-877-302 $30,042 14 payments
A Phase 3 Parallel-Design Open-Label Randomized Controlled Study to Evaluate the Efficacy and Safety of Ly3209590 As A Weekly Basal Insulin Compared to Insulin Glargine in Adults With Type 2 Diabetes on Multiple Daily Injections $28,783 1 payment
M16-100 $27,036 18 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.